Astrazeneca announced that the experimental anti-cancer drug Datopotumab deruxtecan (Dato-DXD) developed in collaboration with Daiichi Sankyo Company did not prolong the survival of patients in a key breast cancer treatment trial compared to chemotherapy. The company stated that it will share these trial results with regulatory institutions and discuss whether the drug should be approved for marketing.